Income Statement ICON Public Limited Company
Equities
ICLR
IE0005711209
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
217.99 USD | -0.11% | +1.15% | +3.95% |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2.81B | 2.8B | 5.48B | 7.74B | 8.12B | |||||
Total Revenues | 2.81B | 2.8B | 5.48B | 7.74B | 8.12B | |||||
Cost of Goods Sold, Total | 1.97B | 1.98B | 3.97B | 5.52B | 5.71B | |||||
Gross Profit | 834M | 820M | 1.51B | 2.22B | 2.41B | |||||
Selling General & Admin Expenses, Total | 339M | 344M | 588M | 783M | 776M | |||||
Stock-Based Compensation (IS) | - | - | 73.84M | - | - | |||||
Depreciation & Amortization - (IS) | 61.55M | 66.13M | 315M | 570M | 586M | |||||
Other Operating Expenses, Total | 400M | 410M | 977M | 1.35B | 1.36B | |||||
Operating Income | 434M | 410M | 534M | 866M | 1.05B | |||||
Interest Expense, Total | -13.28M | -13.02M | -182M | -230M | -337M | |||||
Interest And Investment Income | 6.86M | 2.72M | 574K | 2.34M | 5.01M | |||||
Net Interest Expenses | -6.42M | -10.3M | -182M | -227M | -332M | |||||
Income (Loss) On Equity Invest. | - | -366K | -2.16M | -3.14M | -383K | |||||
EBT, Excl. Unusual Items | 427M | 399M | 350M | 636M | 714M | |||||
Restructuring Charges | - | -18.09M | -31.1M | -31.14M | -45.39M | |||||
Merger & Related Restructuring Charges | -300K | - | -124M | -39.7M | -44.18M | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 427M | 381M | 195M | 565M | 624M | |||||
Income Tax Expense | 51.13M | 47.88M | 41.33M | 59.41M | 11.75M | |||||
Earnings From Continuing Operations | 376M | 333M | 153M | 505M | 612M | |||||
Net Income to Company | 376M | 333M | 153M | 505M | 612M | |||||
Minority Interest | -1.87M | -633K | - | - | - | |||||
Net Income - (IS) | 374M | 332M | 153M | 505M | 612M | |||||
Preferred Dividend and Other Adjustments | 5.05M | 4.52M | - | - | - | |||||
Net Income to Common Incl Extra Items | 369M | 328M | 153M | 505M | 612M | |||||
Net Income to Common Excl. Extra Items | 369M | 328M | 153M | 505M | 612M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6.85 | 6.2 | 2.28 | 6.2 | 7.46 | |||||
Basic EPS - Continuing Operations | 6.85 | 6.2 | 2.28 | 6.2 | 7.46 | |||||
Basic Weighted Average Shares Outstanding | 53.86M | 52.86M | 67.11M | 81.53M | 82.1M | |||||
Net EPS - Diluted | 6.79 | 6.15 | 2.25 | 6.13 | 7.4 | |||||
Diluted EPS - Continuing Operations | 6.79 | 6.15 | 2.25 | 6.13 | 7.4 | |||||
Diluted Weighted Average Shares Outstanding | 54.33M | 53.28M | 68.07M | 82.47M | 82.72M | |||||
Normalized Basic EPS | 4.92 | 4.7 | 3.26 | 4.87 | 5.43 | |||||
Normalized Diluted EPS | 4.88 | 4.67 | 3.21 | 4.82 | 5.39 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 495M | 476M | 849M | 1.44B | 1.63B | |||||
EBITA | 450M | 429M | 774M | 1.33B | 1.51B | |||||
EBIT | 434M | 410M | 534M | 866M | 1.05B | |||||
EBITDAR | 528M | 506M | 899M | 1.49B | 1.68B | |||||
Total Revenues (As Reported) | 2.81B | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 11.98 | 12.57 | 21.25 | 10.52 | 1.88 | |||||
Current Domestic Taxes | 35.96M | 28.96M | 18.47M | 53.25M | 80.43M | |||||
Current Foreign Taxes | 16.72M | 17.98M | 83.48M | 131M | 16.72M | |||||
Total Current Taxes | 52.67M | 46.95M | 102M | 184M | 97.15M | |||||
Deferred Domestic Taxes | 2.83M | 1.65M | 553K | -6.17M | 45.25M | |||||
Deferred Foreign Taxes | -4.37M | -727K | -61.17M | -119M | -131M | |||||
Total Deferred Taxes | -1.54M | 927K | -60.62M | -125M | -85.4M | |||||
Normalized Net Income | 265M | 249M | 219M | 397M | 446M | |||||
Interest on Long-Term Debt | - | - | - | - | 337M | |||||
Non-Cash Pension Expense | 263K | -326K | 119K | -358K | -314K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 8.09M | 7.02M | - | - | - | |||||
Selling and Marketing Expenses | 8.09M | 7.02M | - | - | - | |||||
Net Rental Expense, Total | 33M | 30.15M | 49.9M | 52.72M | 45.72M | |||||
Imputed Operating Lease Interest Expense | 8.72M | 7.07M | 23.96M | 18.5M | 28.09M | |||||
Imputed Operating Lease Depreciation | 24.28M | 23.08M | 25.94M | 34.22M | 17.63M | |||||
Stock-Based Comp., COGS (Total) | 14.78M | 8.56M | 18.55M | 22.85M | 26.6M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 12.04M | 17.71M | 41.46M | 47.67M | 29.07M | |||||
Stock-Based Comp., Other (Total) | - | - | 73.84M | - | - | |||||
Total Stock-Based Compensation | 26.82M | 26.27M | 134M | 70.52M | 55.67M |